Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

What Happened? A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation ...

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $118 from $115 and keeps a Neutral rating on the shares. The ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why BIIB stock is a hold.

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare disease drugs largely countered declining sales of its older multiple ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with Eisai (ESALF). Read more here.

Nearly 40% of Biogen investors said they want a CEO with a track record of successful business development, either through in-licensing deals or acquisitions, an RBC Capital Markets survey shows.

Biogen's quarterly revenue fell 6%, in part due to lower sales of the company's multiple sclerosis drugs in the U.S. due to cheaper, generic competition.

NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...